XW0 New Technology
Group XW0 is in Section X (New Technology). The remaining four characters of each code complete the procedure description. This group contains 178 codes for FY2027.
| Code | Description |
|---|---|
XW01318 | Introduction of Daratumumab and Hyaluronidase-fihj into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8 |
XW01329 | Introduction of Talquetamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9 |
XW01348 | Introduction of Teclistamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8 |
XW0134C | Introduction of Elamipretide into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 12 |
XW0136A | Introduction of Dasiglucagon into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 10 |
XW013F5 | Introduction of Other New Technology Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5 |
XW013G6 | Introduction of REGN-COV2 Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 |
XW013H6 | Introduction of Other New Technology Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 |
XW013K6 | Introduction of Leronlimab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 |
XW013L9 | Introduction of Elranatamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9 |
XW013S6 | Introduction of COVID-19 Vaccine Dose 1 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 |
XW013S9 | Introduction of Epcoritamab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9 |
XW013T6 | Introduction of COVID-19 Vaccine Dose 2 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 |
XW013TB | Introduction of Rozanolixizumab-noli Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 11 |
XW013U6 | Introduction of COVID-19 Vaccine into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 |
XW013V7 | Introduction of COVID-19 Vaccine Dose 3 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7 |
XW013W5 | Introduction of Caplacizumab into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5 |
XW013W7 | Introduction of COVID-19 Vaccine Booster into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7 |
XW020D8 | Introduction of Engineered Allogeneic Thymus Tissue into Muscle, Open Approach, New Technology Group 8 |
XW023S6 | Introduction of COVID-19 Vaccine Dose 1 into Muscle, Percutaneous Approach, New Technology Group 6 |
XW023T6 | Introduction of COVID-19 Vaccine Dose 2 into Muscle, Percutaneous Approach, New Technology Group 6 |
XW023U6 | Introduction of COVID-19 Vaccine into Muscle, Percutaneous Approach, New Technology Group 6 |
XW023V7 | Introduction of COVID-19 Vaccine Dose 3 into Muscle, Percutaneous Approach, New Technology Group 7 |
XW023W7 | Introduction of COVID-19 Vaccine Booster into Muscle, Percutaneous Approach, New Technology Group 7 |
XW023Y7 | Introduction of Other New Technology Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7 |
XW03308 | Introduction of Spesolimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 8 |
XW0330B | Introduction of Alpha1-proteinase Inhibitor into Peripheral Vein, Percutaneous Approach, New Technology Group 11 |
XW0331B | Introduction of Anitocabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 11 |
XW0333A | Introduction of Bentracimab, Ticagrelor Reversal Agent into Peripheral Vein, Percutaneous Approach, New Technology Group 10 |
XW0334A | Introduction of Cefepime-taniborbactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 10 |
XW03357 | Introduction of Narsoplimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
XW03358 | Introduction of Mosunetuzumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 8 |
XW0335A | Introduction of Ceftobiprole Medocaril Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 10 |
XW03368 | Introduction of Afamitresgene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8 |
XW0336C | Introduction of Landiolol Antiarrhythmic into Peripheral Vein, Percutaneous Approach, New Technology Group 12 |
XW03372 | Introduction of Inactivated Coagulation Factor Xa into Peripheral Vein, Percutaneous Approach, New Technology Group 2 |
XW03378 | Introduction of Tabelecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8 |
XW0337C | Introduction of Zimislecel Allogeneic Stem Cell-Derived Islet Cell Therapy into Peripheral Vein, Percutaneous Approach, New Technology Group 12 |
XW03388 | Introduction of Treosulfan into Peripheral Vein, Percutaneous Approach, New Technology Group 8 |
XW0338A | Introduction of Obecabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 10 |
XW03396 | Introduction of Ceftolozane/Tazobactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6 |
XW03398 | Introduction of Inebilizumab-cdon into Peripheral Vein, Percutaneous Approach, New Technology Group 8 |
XW0339A | Introduction of Odronextamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 10 |
XW033A7 | Introduction of Ciltacabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
XW033B3 | Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 3 |
XW033BA | Introduction of Orca-T Allogeneic T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 10 |
XW033C7 | Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
XW033CA | Introduction of Zanidatamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 10 |
XW033DA | Introduction of Donislecel-jujn Allogeneic Pancreatic Islet Cellular Suspension into Peripheral Vein, Percutaneous Approach, New Technology Group 10 |
XW033E5 | Introduction of Remdesivir Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5 |
XW033F3 | Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 3 |
XW033F5 | Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 5 |
XW033FA | Introduction of Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy into Peripheral Vein, Percutaneous Approach, New Technology Group 10 |
XW033FB | Introduction of Valoctocogene Roxaparvovec-rvox into Peripheral Vein, Percutaneous Approach, New Technology Group 11 |
XW033G5 | Introduction of Sarilumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5 |
XW033G6 | Introduction of REGN-COV2 Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6 |
XW033G7 | Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
XW033H5 | Introduction of Tocilizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5 |
XW033H6 | Introduction of Other New Technology Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6 |
XW033H7 | Introduction of Axicabtagene Ciloleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
XW033J7 | Introduction of Tisagenlecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
XW033K7 | Introduction of Idecabtagene Vicleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
XW033K9 | Introduction of Sulbactam-Durlobactam into Peripheral Vein, Percutaneous Approach, New Technology Group 9 |
XW033L6 | Introduction of CD24Fc Immunomodulator into Peripheral Vein, Percutaneous Approach, New Technology Group 6 |
XW033L7 | Introduction of Lifileucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
XW033M7 | Introduction of Brexucabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
XW033MA | Introduction of Emapalumab-lzsg Anti-IFNy Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 10 |
XW033N7 | Introduction of Lisocabtagene Maraleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
XW033NA | Introduction of Tarlatamab-dlle Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 10 |
XW033P9 | Introduction of Glofitamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 9 |
XW033PB | Introduction of Aztreonam-avibactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 11 |
XW033Q5 | Introduction of Tagraxofusp-erzs Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5 |
XW033Q9 | Introduction of Posoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 9 |
XW033QB | Introduction of Iloprost into Peripheral Vein, Percutaneous Approach, New Technology Group 11 |
XW033R9 | Introduction of Rezafungin into Peripheral Vein, Percutaneous Approach, New Technology Group 9 |
XW033RB | Introduction of Letetresgene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 11 |
XW033S5 | Introduction of Iobenguane I-131 Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5 |
XW033W5 | Introduction of Caplacizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5 |
XW033WB | Introduction of Fosfomycin Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 11 |
XW04308 | Introduction of Spesolimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 8 |
XW0430B | Introduction of Alpha1-proteinase Inhibitor into Central Vein, Percutaneous Approach, New Technology Group 11 |
XW0431B | Introduction of Anitocabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 11 |
XW0433A | Introduction of Bentracimab, Ticagrelor Reversal Agent into Central Vein, Percutaneous Approach, New Technology Group 10 |
XW0434A | Introduction of Cefepime-taniborbactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 10 |
XW04357 | Introduction of Narsoplimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7 |
XW04358 | Introduction of Mosunetuzumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 8 |
XW0435A | Introduction of Ceftobiprole Medocaril Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 10 |
XW04368 | Introduction of Afamitresgene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8 |
XW0436C | Introduction of Landiolol Antiarrhythmic into Central Vein, Percutaneous Approach, New Technology Group 12 |
XW04372 | Introduction of Inactivated Coagulation Factor Xa into Central Vein, Percutaneous Approach, New Technology Group 2 |
XW04378 | Introduction of Tabelecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8 |
XW04388 | Introduction of Treosulfan into Central Vein, Percutaneous Approach, New Technology Group 8 |
XW0438A | Introduction of Obecabtagene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 10 |
XW04396 | Introduction of Ceftolozane/Tazobactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6 |
XW04398 | Introduction of Inebilizumab-cdon into Central Vein, Percutaneous Approach, New Technology Group 8 |
XW0439A | Introduction of Odronextamab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 10 |
XW043A7 | Introduction of Ciltacabtagene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 7 |
XW043B3 | Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 3 |
XW043BA | Introduction of Orca-T Allogeneic T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 10 |
XW043C7 | Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7 |
XW043CA | Introduction of Zanidatamab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 10 |
XW043E5 | Introduction of Remdesivir Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5 |
XW043F3 | Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 3 |
XW043F5 | Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 5 |
XW043FA | Introduction of Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy into Central Vein, Percutaneous Approach, New Technology Group 10 |
XW043FB | Introduction of Valoctocogene Roxaparvovec-rvox into Central Vein, Percutaneous Approach, New Technology Group 11 |
XW043G5 | Introduction of Sarilumab into Central Vein, Percutaneous Approach, New Technology Group 5 |
XW043G6 | Introduction of REGN-COV2 Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6 |
XW043G7 | Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7 |
XW043H5 | Introduction of Tocilizumab into Central Vein, Percutaneous Approach, New Technology Group 5 |
XW043H6 | Introduction of Other New Technology Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6 |
XW043H7 | Introduction of Axicabtagene Ciloleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7 |
XW043J7 | Introduction of Tisagenlecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7 |
XW043K7 | Introduction of Idecabtagene Vicleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7 |
XW043K9 | Introduction of Sulbactam-Durlobactam into Central Vein, Percutaneous Approach, New Technology Group 9 |
XW043L6 | Introduction of CD24Fc Immunomodulator into Central Vein, Percutaneous Approach, New Technology Group 6 |
XW043L7 | Introduction of Lifileucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7 |
XW043M7 | Introduction of Brexucabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7 |
XW043MA | Introduction of Emapalumab-lzsg Anti-IFNy Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 10 |
XW043N7 | Introduction of Lisocabtagene Maraleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7 |
XW043NA | Introduction of Tarlatamab-dlle Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 10 |
XW043P9 | Introduction of Glofitamab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 9 |
XW043PB | Introduction of Aztreonam-avibactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 11 |
XW043Q5 | Introduction of Tagraxofusp-erzs Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5 |
XW043Q9 | Introduction of Posoleucel into Central Vein, Percutaneous Approach, New Technology Group 9 |
XW043QB | Introduction of Iloprost into Central Vein, Percutaneous Approach, New Technology Group 11 |
XW043R9 | Introduction of Rezafungin into Central Vein, Percutaneous Approach, New Technology Group 9 |
XW043RB | Introduction of Letetresgene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 11 |
XW043S5 | Introduction of Iobenguane I-131 Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5 |
XW043W5 | Introduction of Caplacizumab into Central Vein, Percutaneous Approach, New Technology Group 5 |
XW043WB | Introduction of Fosfomycin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 11 |
XW0534B | Introduction of Somatic Stem Cells into Peripheral Artery, Percutaneous Approach, New Technology Group 11 |
XW053T9 | Introduction of Melphalan Hydrochloride Antineoplastic into Peripheral Artery, Percutaneous Approach, New Technology Group 9 |
XW0632B | Introduction of CPI-601 Enzyme Replacement Therapy into Cerebral Ventricle, Percutaneous Approach, New Technology Group 11 |
XW0DX38 | Introduction of Maribavir Anti-infective into Mouth and Pharynx, External Approach, New Technology Group 8 |
XW0DX82 | Introduction of Uridine Triacetate into Mouth and Pharynx, External Approach, New Technology Group 2 |
XW0DXF5 | Introduction of Other New Technology Therapeutic Substance into Mouth and Pharynx, External Approach, New Technology Group 5 |
XW0DXJ9 | Introduction of Quizartinib Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 9 |
XW0DXK8 | Introduction of Sabizabulin into Mouth and Pharynx, External Approach, New Technology Group 8 |
XW0DXM6 | Introduction of Baricitinib into Mouth and Pharynx, External Approach, New Technology Group 6 |
XW0DXN9 | Introduction of SER-109 into Mouth and Pharynx, External Approach, New Technology Group 9 |
XW0DXVB | Introduction of Xanomeline and Trospium Chloride into Mouth and Pharynx, External Approach, New Technology Group 11 |
XW0E33B | Introduction of Lunsotogene Parvec-cwha via Intracochlear Infusion into Ear(s), Percutaneous Approach, New Technology Group 11 |
XW0G738 | Introduction of Maribavir Anti-infective into Upper GI, Via Natural or Artificial Opening, New Technology Group 8 |
XW0G7K8 | Introduction of Sabizabulin into Upper GI, Via Natural or Artificial Opening, New Technology Group 8 |
XW0G7M6 | Introduction of Baricitinib into Upper GI, Via Natural or Artificial Opening, New Technology Group 6 |
XW0G886 | Introduction of Mineral-based Topical Hemostatic Agent into Upper GI, Via Natural or Artificial Opening Endoscopic, New Technology Group 6 |
XW0H738 | Introduction of Maribavir Anti-infective into Lower GI, Via Natural or Artificial Opening, New Technology Group 8 |
XW0H7K8 | Introduction of Sabizabulin into Lower GI, Via Natural or Artificial Opening, New Technology Group 8 |
XW0H7M6 | Introduction of Baricitinib into Lower GI, Via Natural or Artificial Opening, New Technology Group 6 |
XW0H7X8 | Introduction of Broad Consortium Microbiota-based Live Biotherapeutic Suspension into Lower GI, Via Natural or Artificial Opening, New Technology Group 8 |
XW0H886 | Introduction of Mineral-based Topical Hemostatic Agent into Lower GI, Via Natural or Artificial Opening Endoscopic, New Technology Group 6 |
XW0J3HA | Introduction of Paclitaxel-Coated Balloon Technology, One Balloon into Coronary Artery, One Artery, Percutaneous Approach, New Technology Group 10 |
XW0J3JA | Introduction of Paclitaxel-Coated Balloon Technology, Two Balloons into Coronary Artery, One Artery, Percutaneous Approach, New Technology Group 10 |
XW0J3KA | Introduction of Paclitaxel-Coated Balloon Technology, Three Balloons into Coronary Artery, One Artery, Percutaneous Approach, New Technology Group 10 |
XW0J3LA | Introduction of Paclitaxel-Coated Balloon Technology, Four or More Balloons into Coronary Artery, One Artery, Percutaneous Approach, New Technology Group 10 |
XW0K3HA | Introduction of Paclitaxel-Coated Balloon Technology, One Balloon into Coronary Artery, Two Arteries, Percutaneous Approach, New Technology Group 10 |
XW0K3JA | Introduction of Paclitaxel-Coated Balloon Technology, Two Balloons into Coronary Artery, Two Arteries, Percutaneous Approach, New Technology Group 10 |
XW0K3KA | Introduction of Paclitaxel-Coated Balloon Technology, Three Balloons into Coronary Artery, Two Arteries, Percutaneous Approach, New Technology Group 10 |
XW0K3LA | Introduction of Paclitaxel-Coated Balloon Technology, Four or More Balloons into Coronary Artery, Two Arteries, Percutaneous Approach, New Technology Group 10 |
XW0L3HA | Introduction of Paclitaxel-Coated Balloon Technology, One Balloon into Coronary Artery, Three Arteries, Percutaneous Approach, New Technology Group 10 |
XW0L3JA | Introduction of Paclitaxel-Coated Balloon Technology, Two Balloons into Coronary Artery, Three Arteries, Percutaneous Approach, New Technology Group 10 |
XW0L3KA | Introduction of Paclitaxel-Coated Balloon Technology, Three Balloons into Coronary Artery, Three Arteries, Percutaneous Approach, New Technology Group 10 |
XW0L3LA | Introduction of Paclitaxel-Coated Balloon Technology, Four or More Balloons into Coronary Artery, Three Arteries, Percutaneous Approach, New Technology Group 10 |
XW0M3HA | Introduction of Paclitaxel-Coated Balloon Technology, One Balloon into Coronary Artery, Four or More Arteries, Percutaneous Approach, New Technology Group 10 |
XW0M3JA | Introduction of Paclitaxel-Coated Balloon Technology, Two Balloons into Coronary Artery, Four or More Arteries, Percutaneous Approach, New Technology Group 10 |
XW0M3KA | Introduction of Paclitaxel-Coated Balloon Technology, Three Balloons into Coronary Artery, Four or More Arteries, Percutaneous Approach, New Technology Group 10 |
XW0M3LA | Introduction of Paclitaxel-Coated Balloon Technology, Four or More Balloons into Coronary Artery, Four or More Arteries, Percutaneous Approach, New Technology Group 10 |
XW0Q316 | Introduction of Eladocagene exuparvovec into Cranial Cavity and Brain, Percutaneous Approach, New Technology Group 6 |
XW0Q35C | Introduction of Ifezuntirgene Inilparvovec into Cranial Cavity and Brain, Percutaneous Approach, New Technology Group 12 |
XW0U0CC | Introduction of Recombinant Human Bone Morphogenetic Protein-2 with Collagen Scaffold into Joints, Open Approach, New Technology Group 12 |
XW0U0GA | Introduction of Vancomycin Hydrochloride and Tobramycin Sulfate Anti-Infective, Temporary Irrigation Spacer System into Joints, Open Approach, New Technology Group 10 |
XW0U0XB | Introduction of Peptide Enhanced Bone Void Filler into Joints, Open Approach, New Technology Group 11 |
XW0U3XB | Introduction of Peptide Enhanced Bone Void Filler into Joints, Percutaneous Approach, New Technology Group 11 |
XW0U4XB | Introduction of Peptide Enhanced Bone Void Filler into Joints, Percutaneous Endoscopic Approach, New Technology Group 11 |
XW0V0BC | Introduction of Vancomycin-eluting Bone Void Filler into Bones, Open Approach, New Technology Group 12 |
XW0V0P7 | Introduction of Gentamicin-eluting Bone Void Filler into Bones, Open Approach, New Technology Group 7 |
XW0V3WA | Introduction of AGN1 Bone Void Filler into Bones, Percutaneous Approach, New Technology Group 10 |
Search ICD-10-PCS for XW0 and related codes
Advertisement